Hana Biosciences (HNAB) Receives US Oprhan Drug Status for Marqibo

June 30, 2008 7:32 AM EDT

Hana Biosciences (Nasdaq: HNAB) today announced that the U.S. FDA has granted orphan drug designation for Marqibo(r) for the treatment of adult patients with metastatic uveal melanoma. Orphan drug designation offers significant benefits to Hana Biosciences, including financial incentives and market exclusivity for a period of seven years.

Hana is currently conducting a Phase 2 clinical trial to assess the efficacy of Marqibo as determined by Disease Control Rate in patients with metastatic malignant uveal melanoma. Secondary objectives are to assess the safety and anti-tumor activity of Marqibo as determined by response rate, progression-free survival, and overall survival. The Phase 2 trial is currently being conducted at the University of Texas MD Anderson Cancer Center.

Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care.

Related Categories

FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?